FluzoparibAlternative Names: SHR 3162
Latest Information Update: 01 Feb 2017
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Phase Unknown Gastric cancer
Most Recent Events
- 18 Jan 2017 Jiangsu HengRui Medicine plans a phase I trial for Gastric cancer (Combination therapy, Recurrent, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT03026881)
- 21 Dec 2016 Investigation in Gastric cancer in China (PO) before December 2016
- 01 Oct 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT02575651)